Access the full text.
Sign up today, get DeepDyve free for 14 days.
Eric Be, Eric Be, E. Collisson, Joshua Campbell, Angela Brooks, A. Berger, William Lee, J. Chmielecki, D. Beer, L. Cope, C. Creighton, Ludmila Danilova, L. Ding, G. Getz, P. Hammerman, D. Hayes, Bryan Hernandez, J. Herman, J. Heymach, I. Jurisica, R. Kucherlapati, D. Kwiatkowski, M. Ladanyi, Gordon Robertson, N. Schultz, R. Shen, Rileen Sinha, C. Sougnez, M. Tsao, W. Travis, J. Weinstein, D. Wigle, M. Wilkerson, Andy Chu, A. Cherniack, Angela Hadjipanayis, Mara Rosenberg, D. Weisenberger, P. Laird, Amie Radenbaugh, Singer Ma, Joshua Stuart, Lauren Byers, S. Baylin, R. Govindan, M. Meyerson, Mara Li, S. Gabriel, K. Cibulskis, Jaegil Kim, C. Stewart, Lee Lichtenstein, E. Lander, M. Lawrence, Cyriac M, C. Kandoth, R. Fulton, L. Fulton, M. McLellan, R. Wilson, K. Ye, C. Fronick, Christopher Maher, Christopher Miller, M. Wendl, Christopher Cabanski, E. Mardis, C. Wheeler, David Wheeler, Miruna Dhalla, M. Balasundaram, Y. Butterfield, R. Carlsen, E. Chuah, Noreen Dhalla, R. Guin, Carrie Hirst, Darlene Lee, H. Li, Michael Mayo, Richard Moore, A. Mungall, J. Schein, Payal Sipahimalani, Angela Tam, R. Varhol, A. Robertson, N. Wye, N. Thiessen, R. Holt, Steven Jones, M. Marra, Joshua Hodi, M. Imieliński, R. Onofrio, Eran Hodis, Travis Zack, E. Helman, Chandra Pedamallu, J. Mesirov, G. Saksena, S. Schumacher, S. Carter, L. Garraway, R. Beroukhim, Angela Re, Semin Lee, Harshad Mahadeshwar, A. Pantazi, A. Protopopov, X. Ren, S. Seth, Xingzhi Song, Jiabin Tang, Lixing Yang, Jianhua Zhang, Peng-Chieh Chen, Michael Parfenov, Andrew Xu, Netty Santoso, L. Chin, Peter Park, Katherine T, K. Hoadley, J. Auman, S. Meng, Yan Shi, Elizabeth Buda, S. Waring, Umadevi Veluvolu, Donghui Tan, P. Mieczkowski, Corbin Jones, J. Simons, Matthew Soloway, T. Bodenheimer, S. Jefferys, J. Roach, A. Hoyle, Junyuan Wu, S. Balu, Darshan Singh, J. Prins, J. Marron, J. Parker, C. Perou, Jinze Liu, Leslie Bootwalla, D. Maglinte, Philip Lai, M. Bootwalla, D. Berg, Timothy Jr, Mara Mallard, Juok Cho, D. Dicara, David Heiman, Pei Lin, William Mallard, Douglas Voet, Hailei Zhang, L. Zou, M. Noble, N. Gehlenborg, H. Thorvaldsdóttir, Marc-Danie Nazaire, Jim Robinson, William Gross, B. Aksoy, G. Ciriello, B. Taylor, Gideon Dresdner, Jianjiong Gao, Benjamin Gross, V. Seshan, B. Reva, Rileen Sinha, S. Sumer, Nils Weinhold, C. Sander, Sam Haussler, S. Ng, Jingchun Zhu, C. Benz, C. Yau, D. Haussler, P. Spellman, Matthew Perou, P. Kimes, Bradley Liu, B. Broom, Jing Wang, Yiling Lu, Patrick Ng, L. Diao, Wenbin Liu, C. Amos, R. Akbani, G. Mills, Erin Gardn, Erin Curley, J. Paulauskis, Kevin Lau, S. Morris, T. Shelton, D. Mallery, J. Gardner, R. Penny, Charles Tarvin, Charles Saller, Katherine Tarvin, W. Richards, Robert Bryant, R. Cerfolio, A. Bryant, Daniel Farver, D. Raymond, N. Pennell, C. Farver, Christine Raben, Christine Czerwinski, L. Huelsenbeck-Dill, M. Iacocca, N. Petrelli, B. Rabeno, Jennifer Brown, Thomas Bauer, Oleg Nemirovich-Dan, O. Dolzhanskiy, O. Potapova, D. Rotin, Olga Voronina, Elena Nemirovich-Danchenko, K. Fedosenko, Anthony Sica, A. Gal, M. Behera, S. Ramalingam, G. Sica, Douglas Weaver, D. Flieder, J. Boyd, J. Weaver, Bernard Thinh, B. Kohl, Dang Thinh, G. Sandusky, Hartmut Juhl, Edwina Duhig, Peter Brock, P. Illei, E. Gabrielson, James Shin, Beverly Lee, Kristen Rodgers, D. Trusty, M. Brock, Christina Sullivan, C. Williamson, E. Burks, K. Rieger-Christ, A. Holway, T. Sullivan, Dennis Kosari, M. Asiedu, F. Kosari, William Rusch, N. Rekhtman, M. Zakowski, V. Rusch, Paul Owusu-Sarpong, Paul Zippile, James Suh, H. Pass, C. Goparaju, Y. Owusu-Sarpong, John Albert, John Bartlett, S. Kodeeswaran, J. Parfitt, H. Sekhon, Monique Albert, John Myers, J. Eckman, J. Myers, Richard Gaudioso, R. Cheney, Carl Morrison, Carmelo Gaudioso, Jeffrey Liptay, J. Borgia, P. Bonomi, M. Pool, M. Liptay, Fedor Zaytseva, F. Moiseenko, I. Zaytseva, Hendrik Muley, H. Dienemann, M. Meister, P. Schnabel, T. Muley, M. Peifer, Carmen Egea, C. Gomez-Fernandez, Lynn Herbert, Sophie Egea, Mei Kimryn, Mei Huang, L. Thorne, L. Boice, Ashley Salazar, W. Funkhouser, W. Rathmell, Rajiv Siegfried, R. Dhir, S. Yousem, S. Dacic, F. Schneider, J. Siegfried, R. Hajek, Mark Meyers, M. Watson, Sandra McDonald, B. Meyers, Belinda Bowman, B. Clarke, I. Yang, K. Fong, L. Hunter, M. Windsor, R. Bowman, Solange Letovanec, Solange Peters, I. Letovanec, K. Khan, Mark Pot, M. Jensen, E. Snyder, Deepak Srinivasan, A. Kahn, J. Baboud, D. Pot, Kenna Tarnuz, Kenna Shaw, Margi Sheth, Tanja Davidsen, John Demchok, Liming Yang, Zhining Wang, R. Tarnuzzer, Jean Zenklusen, Bradley Sofia, B. Ozenberger, H. Sofia, William Illei, Edwina Duhig (2014)
Comprehensive molecular profiling of lung adenocarcinomaNature, 511
S. Rothschild, Paul Leger, E. Castellanos, R. Pillai, S. York, Leora Horn (2017)
91PD_PRResponse to salvage chemotherapy following exposure to PD-1/PD-L1 inhibitors in patients with NSCLCAnnals of Oncology, 28
A. Shaw, S. Ou, Y. Bang, D. Camidge, B. Solomon, R. Salgia, Gregory Riely, M. Varella-Garcia, G. Shapiro, D. Costa, R. Doebele, L. Le, Zongli Zheng, Weiwei Tan, P. Stephenson, S. Shreeve, L. Tye, J. Christensen, K. Wilner, Jeffrey Clark, A. Iafrate (2014)
Crizotinib in ROS1-rearranged non-small-cell lung cancer.The New England journal of medicine, 371 21
T. Winton, R. Livingston, David Johnson, J. Rigas, M. Johnston, C. Butts, Y. Cormier, G. Goss, R. Inculet, E. Vallières, W. Fry, D. Bethune, J. Ayoub, K. Ding, L. Seymour, B. Graham, M. Tsao, D. Gandara, K. Kesler, T. Demmy, F. Shepherd (2005)
Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer.The New England journal of medicine, 352 25
L. Paz-Ares, F. Marinis, M. Dediu, Michael Thomas, J. Pujol, P. Bidoli, O. Molinier, T. Sahoo, E. Laack, M. Reck, J. Corral, S. Melemed, W. John, N. Chouaki, A. Zimmermann, C. Visseren-Grul, C. Gridelli (2013)
PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 23
S. Verma, D. Miles, L. Gianni, I. Krop, M. Welslau, J. Baselga, M. Pegram, D. Oh, V. Diéras, E. Guardino, L. Fang, Michael Lu, S. Olsen, K. Blackwell (2012)
Trastuzumab emtansine for HER2-positive advanced breast cancer.The New England journal of medicine, 367 19
N. Thatcher, F. Hirsch, A. Luft, A. Szczesna, T. Ciuleanu, M. Dediu, R. Ramlau, R. Galiulin, B. Bálint, G. Losonczy, A. Każarnowicz, Keunchil Park, C. Schumann, M. Reck, H. Depenbrock, S. Nanda, Anamarija Kruljac-Letunic, R. Kurek, L. Paz-Ares, M. Socinski (2015)
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.The Lancet. Oncology, 16 7
R. Rosell, E. Carcereny, R. Gervais, A. Vergnenègre, B. Massutí, E. Felip, R. Palmero, R. García-Gómez, C. Pallarés, J. Sánchez, R. Porta, M. Cobo, P. Garrido, F. Longo, T. Morán, A. Insa, F. Marinis, R. Corre, I. Bover, A. Illiano, É. Dansin, J. Castro, M. Milella, N. Reguart, G. Altavilla, U. Jiménez, M. Provencio, M. Moreno, J. Terrasa, J. Muñoz-Langa, J. Valdivia, D. Isla, M. Dómine, O. Molinier, J. Mazières, N. Baize, R. García-Campelo, G. Robinet, D. Rodríguez-Abreu, G. López-Vivanco, V. Gebbia, Lioba Ferrera-Delgado, P. Bombaron, R. Bernabé, A. Bearz, Á. Artal, E. Cortesi, C. Rolfo, M. Sánchez-Ronco, A. Drozdowskyj, C. Queralt, I. Aguirre, J. Ramírez, J. Sánchez, M. Molina, M. Taron, L. Paz-Ares (2012)
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.The Lancet. Oncology, 13 3
M. Socinski, I. Bondarenko, N. Karaseva, A. Makhson, I. Vynnychenko, I. Okamoto, J. Hon, V. Hirsh, P. Bhar, Hui Zhang, J. Iglesias, M. Renschler (2012)
Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 17
A. Sandler, R. Gray, M. Perry, J. Brahmer, J. Schiller, A. Dowlati, R. Lilenbaum, David Johnson (2006)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.The New England journal of medicine, 355 24
E. Garon, N. Rizvi, R. Hui, N. Leighl, A. Balmanoukian, J. Eder, A. Patnaik, C. Aggarwal, M. Gubens, L. Horn, E. Carcereny, M. Ahn, E. Felip, Jong-Seok Lee, M. Hellmann, O. Hamid, J. Goldman, J. Soria, M. Dolled-Filhart, R. Rutledge, Jin Zhang, J. Lunceford, Reshma Rangwala, G. Lubiniecki, C. Roach, K. Emancipator, L. Gandhi (2015)
Pembrolizumab for the treatment of non-small-cell lung cancer.The New England journal of medicine, 372 21
M. Kreuter, J. Vansteenkiste, J. Fischer, W. Eberhardt, H. Zabeck, J. Kollmeier, M. Serke, N. Frickhofen, M. Reck, W. Engel‐Riedel, S. Neumann, M. Thomeer, C. Schumann, P. Leyn, T. Graeter, G. Stamatis, I. Zuna, F. Griesinger, Mike Thomas (2013)
Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study.Annals of oncology : official journal of the European Society for Medical Oncology, 24 4
S. Popat, A. Mellemgaard, M. Reck, C. Hastedt, I. Griebsch (2017)
Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer of adenocarcinoma histology: a network meta-analysis vs new therapeutic options.Future oncology, 13 13
B. Solomon, T. Mok, Dong-Wan Kim, Yi-long Wu, K. Nakagawa, T. Mekhail, E. Felip, F. Cappuzzo, J. Paolini, T. Usari, S. Iyer, A. Reisman, K. Wilner, J. Tursi, F. Blackhall (2014)
First-line crizotinib versus chemotherapy in ALK-positive lung cancer.The New England journal of medicine, 371 23
E. Garon, T. Ciuleanu, O. Arrieta, K. Prabhash, K. Syrigos, T. Goksel, Keunchil Park, V. Gorbunova, R. Kowalyszyn, J. Pikiel, G. Czyżewicz, S. Orlov, C. Lewanski, Michael Thomas, P. Bidoli, S. Dakhil, S. Gans, Joo‐Hang Kim, A. Grigorescu, N. Karaseva, M. Reck, F. Cappuzzo, Ekaterine Alexandris, A. Sashegyi, S. Yurasov, M. Pérol (2014)
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trialThe Lancet, 384
D. Planchard, S. Popat, K. Kerr, S. Novello, E. Smit, C. Faivre-Finn, T. Mok, M. Reck, P. Schil, M. Hellmann, S. Peters (2018)
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Annals of oncology : official journal of the European Society for Medical Oncology, 29 Supplement_4
J. Douillard, R. Rosell, M. Lena, F. Carpagnano, R. Ramlau, J. Gonzáles-Larriba, T. Grodzki, J. Pereira, A. Groumellec, V. Lorusso, C. Clary, A. Torres, J. Dahabreh, P. Souquet, J. Astudillo, P. Fournel, A. Artal-Cortes, J. Jassem, L. Koubková, P. His, M. Riggi, P. Hurteloup (2006)
Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial.The Lancet. Oncology, 7 9
C. Langer, S. Gadgeel, H. Borghaei, V. Papadimitrakopoulou, A. Patnaik, S. Powell, R. Gentzler, R. Martins, J. Stevenson, S. Jalal, A. Panwalkar, J. Yang, M. Gubens, L. Sequist, M. Awad, J. Fiore, Y. Ge, H. Raftopoulos, L. Gandhi (2016)
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.The Lancet. Oncology, 17 11
M. Reck, D. Rodríguez-Abreu, A. Robinson, R. Hui, T. Csőszi, A. Fülöp, M. Gottfried, N. Peled, A. Tafreshi, S. Cuffe, M. O'Brien, Suman Rao, K. Hotta, M. Leiby, G. Lubiniecki, Shentu Yue, Reshma Rangwala, J. Brahmer (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.The New England journal of medicine, 375 19
J. Vansteenkiste, D. Ruysscher, W. Eberhardt, E. Lim, S. Senan, E. Felip, Solange Peters (2013)
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Annals of oncology : official journal of the European Society for Medical Oncology, 24 Suppl 6
G. Schmid‐Bindert, W. Engel‐Riedel, M. Reck, W. Schuette, J. Stöhlmacher, J. Fischer, J. Mazières, C. Chouaid, M. Wolf, N. Viñolas, V. Soldatenkova, V. Ripoche, Tuan Nguyen, C. Visseren-Grul (2015)
A randomized Phase 2 study of pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in patients with completely resected stage IB or II Non-Small-Cell Lung Cancer.Lung cancer, 90 3
T. Stinchcombe, R. Stahel, L. Bubendorf, P. Bonomi, Augusto Villegas, D. Kowalski, C. Baik, D. Isla, Javier Castro, P. López, A. Rittmeyer, M. Tiseo, Sven Stanzel, S. Haas, L. Lam, Michael Lu, S. Peters (2017)
Efficacy, safety, and biomarker results of trastuzumab emtansine (T-DM1) in patients (pts) with previously treated HER2-overexpressing locally advanced or metastatic non-small cell lung cancer (mNSCLC).Journal of Clinical Oncology, 35
J. Pignon, H. Tribodet, G. Scagliotti, J. Douillard, F. Shepherd, R. Stephens, A. Dunant, V. Torri, R. Rosell, L. Seymour, S. Spiro, E. Rolland, R. Fossati, D. Aubert, K. Ding, D. Waller, T. Chevalier (2008)
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 21
F Barlesi S Novello (2016)
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol, 27
G. Scagliotti, P. Parikh, J. Pawel, B. Biesma, J. Vansteenkiste, C. Manegold, P. Serwatowski, U. Gatzemeier, R. Digumarti, M. Zukin, J. Lee, A. Mellemgaard, Keunchil Park, S. Patil, J. Rolski, T. Goksel, F. Marinis, L. Simms, K. Sugarman, D. Gandara (2008)
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 21
H. Borghaei, L. Paz-Ares, L. Horn, D. Spigel, M. Steins, N. Ready, L. Chow, E. Vokes, E. Felip, E. Holgado, F. Barlesi, M. Kohlhäufl, O. Arrieta, M. Burgio, J. Fayette, H. Léna, E. Poddubskaya, D. Gerber, S. Gettinger, C. Rudin, N. Rizvi, L. Crinò, G. Blumenschein, S. Antonia, C. Dorange, C. Harbison, F. Finckenstein, J. Brahmer (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.The New England journal of medicine, 373 17
S. Senan, A. Brade, Lu-hua Wang, J. Vansteenkiste, S. Dakhil, B. Biesma, M. Aguillo, J. Aerts, R. Govindan, B. Rubio-Viqueira, C. Lewanski, D. Gandara, H. Choy, T. Mok, A. Hossain, N. Iscoe, J. Treat, A. Koustenis, B. Antonio, N. Chouaki, E. Vokes (2016)
PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34 9
J. Brahmer, K. Reckamp, P. Baas, L. Crinò, W. Eberhardt, E. Poddubskaya, S. Antonia, A. Płużański, E. Vokes, E. Holgado, D. Waterhouse, N. Ready, J. Gainor, O. Frontera, L. Havel, M. Steins, M. Garassino, J. Aerts, M. Dómine, L. Paz-Ares, M. Reck, C. Baudelet, C. Harbison, B. Lestini, D. Spigel (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.The New England journal of medicine, 373 2
Maicol Mancini, Y. Yarden (2016)
Mutational and network level mechanisms underlying resistance to anti-cancer kinase inhibitors.Seminars in cell & developmental biology, 50
M. Reck, R. Kaiser, A. Mellemgaard, J. Douillard, S. Orlov, M. Krzakowski, J. Pawel, M. Gottfried, I. Bondarenko, M. Liao, Claudia-Nanette Gann, J. Barrueco, B. Gaschler-Markefski, S. Novello (2014)
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.The Lancet. Oncology, 15 2
Summary The last few years have seen an explosion of novel treatment options for patients diagnosed with lung cancer, mostly for those with stage IV non-small cell lung cancer. On the one hand, this was due to the development of modern diagnostic tools permitting accurate molecular diagnoses leading to the identification of several oncogenic driver mutations which can be therapeutically targeted. On the other hand, the advent of immunotherapy in medical oncology in general, but in thoracic oncology in particular, has changed the treatment landscape first in second-line systemic treatment, but recently also in first-line treatment in patients with programmed death ligand-1 (PD-L1) expression in their tumors of >50%. Despite those advances, the majority of patients we treat in our daily routine will still receive chemotherapy: a so-called druggable aberration is only found in approximately 20% of cases. Some 25% present with an activating KRAS mutation, which despite decades of research still cannot be directly targeted. In the remainder, no genomic aberration of direct clinical consequences has been identified. On the other hand, the rate of PD-L1 positivity >50% at diagnosis has been reported to be between 24.9 and 30.2%. Overall, this leaves the majority of patients without any of those options in first-line therapy and they will receive standard of care chemotherapy. This minireview discusses the latest developments in the field of chemotherapy for non-small cell lung cancer.
memo - Magazine of European Medical Oncology – Springer Journals
Published: Sep 1, 2017
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.